Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma

Biliary tract carcinomas (BTC) are malignant tumors with limited therapeutic options. Clinical experiences with anti-EGFR therapies have produced unsatisfactory results. The strategies of combined inhibition of EGFR and MEK1/2 could be a promising therapeutic option in BTC treatment. Preclinical act...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavalloni, Giuliana, Peraldo-Neia, Caterina, Varamo, Chiara, Chiorino, Giovanna, Sassi, Francesco, Aglietta, Massimo, Leone, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239557/
https://www.ncbi.nlm.nih.gov/pubmed/27429047
http://dx.doi.org/10.18632/oncotarget.10587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239557/
https://www.ncbi.nlm.nih.gov/pubmed/27429047
http://dx.doi.org/10.18632/oncotarget.10587

Ejemplares similares